Back

Short- and long-term effects of empagliflozin on sodium balance and fluid regulation in chronic heart failure

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Heart failure therapy across the spectrum Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Venera Bytyqi

University Hospital Erlangen, Erlangen (Germany)

5 More presentations in this session

Presentation thumbnail
Empagliflozin versus dapagliflozin in heart failure
Mr K. Bonnesen (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Early diagnosis of Wild-type Transthyretin Amyloidosis Cardiomyopathy by optimized screening of patients undergoing Carpal Tunnel Syndrome Surgery (CACTuS II)
Mrs S. Fensman (Aarhus N, DK)
Abstract Slides Video
Presentation thumbnail
Home-based rehabilitation in patients with chronic heart failure after acute decompensation: primary results of the PILOT-CRHF trial
Doctor A. Reuser (Leipzig, DE)
Abstract Slides Video
Presentation thumbnail
Efficacy of early angiotensin receptor/neprilysin inhibition in post-myocardial infarction patients: a meta-analysis of randomized controlled trials
Associate Professor C. Hsu (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
Remote rapid titration of heart failure therapies
Doctor A. Abdel-Gadir (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure therapy across the spectrum

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Acute diuretic effect of empagliflozin in de novo heart failure: a secondary analysis of the EMPAG-HF trial
thumbnail
Congress Presentation
Effects of empagliflozin on cardio-renal interaction in heart failure with reduced ejection fraction: results from in-vivo experiments and the CINNAMON-study
thumbnail
Congress Presentation
Renal function in patients with acute decompensated de novo heart failure treated with the SGLT2 inhibitor empagliflozin: a secondary analysis of the EMPAG-HF trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources